Jane Street Group LLC acquired a new stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 61,666 shares of the company’s stock, valued at approximately $795,000.
Several other large investors have also recently bought and sold shares of the company. Bank of Montreal Can bought a new position in Oxford Immunotec Global during the second quarter worth $132,000. State Board of Administration of Florida Retirement System bought a new position in Oxford Immunotec Global during the second quarter worth $140,000. JPMorgan Chase & Co. boosted its stake in Oxford Immunotec Global by 258.0% during the first quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock worth $243,000 after acquiring an additional 14,092 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Oxford Immunotec Global by 84.7% during the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after acquiring an additional 9,658 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Oxford Immunotec Global during the second quarter worth $333,000. 91.78% of the stock is currently owned by institutional investors.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $13.15, for a total value of $39,450.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 86,100 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the completion of the transaction, the chief executive officer now directly owns 539,569 shares in the company, valued at $9,938,860.98. The disclosure for this sale can be found here. Insiders sold 149,100 shares of company stock worth $2,557,612 over the last ninety days. Insiders own 6.61% of the company’s stock.
Several research analysts recently issued reports on the stock. ValuEngine raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th. BidaskClub raised shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 8th. Finally, Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Friday, August 3rd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Oxford Immunotec Global has a consensus rating of “Buy” and a consensus target price of $17.80.
Oxford Immunotec Global stock opened at $16.19 on Tuesday. Oxford Immunotec Global PLC has a 1-year low of $10.00 and a 1-year high of $19.19. The firm has a market capitalization of $421.45 million, a price-to-earnings ratio of -11.90 and a beta of -0.21. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.86 and a current ratio of 5.39.
Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings data on Tuesday, July 31st. The company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The firm had revenue of $29.32 million for the quarter, compared to analyst estimates of $28.58 million. During the same period last year, the firm earned ($0.74) earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts predict that Oxford Immunotec Global PLC will post -0.95 EPS for the current year.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Story: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.